Immunotherapy in Urothelial Cancer: Stop When Achieving a Response, Restart upon Disease Progression

SIMPLE SUMMARY: Immune checkpoint inhibitors (ICI) have dramatically changed the landscape of metastatic urothelial carcinoma (UC). However, optimal duration of treatment with ICI in the metastatic setting remains unclear. On the basis of real-world data from the Netherlands of patients treated with...

Descripción completa

Detalles Bibliográficos
Autores principales: Salhi, Youssra, De Wit, Ronald, Robbrecht, Debbie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378071/
https://www.ncbi.nlm.nih.gov/pubmed/37509315
http://dx.doi.org/10.3390/cancers15143654

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10378071/
https://www.ncbi.nlm.nih.gov/pubmed/37509315
http://dx.doi.org/10.3390/cancers15143654

Ejemplares similares